| 303 Denver Chiropractic Llc | |
|
9898 Rosemont Ave, Suite 204, Lone Tree, CO 80124-4106 | |
| (303) 708-8088 | |
| (303) 795-2000 |
| Full Name | 303 Denver Chiropractic Llc |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 9898 Rosemont Ave, Lone Tree, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154661270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 0006960 (Colorado) | Primary |
| Provider Name | Noel T Kite |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1366780207 PECOS PAC ID: 9234376948 Enrollment ID: I20130516000081 |
News Archive
Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
Ensuring that the sexual partners of patients diagnosed with urethritis are also treated remains a challenge since the traditional methods of partner referral are usually ineffective.
Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.
› Verified 1 days ago
| Provider Name | Ryne E Ibarra |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1881190726 PECOS PAC ID: 0547676595 Enrollment ID: I20210317000829 |
News Archive
Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
Ensuring that the sexual partners of patients diagnosed with urethritis are also treated remains a challenge since the traditional methods of partner referral are usually ineffective.
Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.
› Verified 1 days ago
| Provider Name | Hilary A Darling |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1679177059 PECOS PAC ID: 1951798834 Enrollment ID: I20220422001722 |
News Archive
Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
Ensuring that the sexual partners of patients diagnosed with urethritis are also treated remains a challenge since the traditional methods of partner referral are usually ineffective.
Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.
› Verified 1 days ago
| Provider Name | Travis Early |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1679971170 PECOS PAC ID: 0446575179 Enrollment ID: I20230605002574 |
News Archive
Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
Ensuring that the sexual partners of patients diagnosed with urethritis are also treated remains a challenge since the traditional methods of partner referral are usually ineffective.
Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| 303 Denver Chiropractic Llc 9898 Rosemont Ave, Suite 204, Lone Tree, CO 80124-4106 Ph: (303) 708-8088 | 303 Denver Chiropractic Llc 9898 Rosemont Ave, Suite 204, Lone Tree, CO 80124-4106 Ph: (303) 708-8088 |
News Archive
Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
Ensuring that the sexual partners of patients diagnosed with urethritis are also treated remains a challenge since the traditional methods of partner referral are usually ineffective.
Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.
› Verified 1 days ago
Dr. D. Maxine Sonnenberg, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 9898 Rosemont Ave, Suite 204, Lone Tree, CO 80124 Phone: 303-795-2300 | |
Metro Acute Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 9898 Rosemont Ave Ste 101, Lone Tree, CO 80124 Phone: 303-221-3342 | |
Genesis Chiropractic Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8683 E Lincoln Ave, Lone Tree, CO 80124 Phone: 720-440-1980 | |
Dr. Mckenzie Sue Reifschneider, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 9068 Forsstrom Dr., C-25, Lone Tree, CO 80124 Phone: 303-925-1050 | |
Quantum Health Solutions Group Chiropractor Medicare: Medicare Enrolled Practice Location: 9997 S Yosemite St, Suite 110, Lone Tree, CO 80124 Phone: 720-560-3083 Fax: 877-613-8072 | |
Dr. Tyler Corbin Fowler, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 9068 Forsstrom Dr., C-25, Lone Tree, CO 80124 Phone: 303-925-1050 |